SECOND AMENDMENT TO ASSET TRANSFER AND LICENSE AGREEMENTAsset Transfer and License Agreement • October 7th, 2019 • Baudax Bio, Inc. • Services-misc health & allied services, nec • Delaware
This Second Amendment to Asset Transfer and License Agreement (this “Second Amendment”), dated December 20, 2018, entered into by and between Alkermes Pharma Ireland Limited, a private company limited by shares and incorporated in Ireland (“APIL”), and Recro Gainesville LLC (as successor to DV Technology LLC), a Massachusetts limited liability company (“Recro” or “Purchaser”), amends that certain Asset Transfer and License Agreement, dated as of April 10, 2015 and amended on December 23, 2015, by and among the parties hereto (as so amended, the “Agreement”).
AMENDMENT TO ASSET TRANSFER AND LICENSE AGREEMENTAsset Transfer and License Agreement • October 7th, 2019 • Baudax Bio, Inc. • Services-misc health & allied services, nec • Delaware
This AMENDMENT (the “Amendment”) is dated as of December 23, 2015 (the “Amendment Effective Date”) to the Asset Transfer and License Agreement (the “Agreement”) dated as of April 10, 2015 between Alkermes Pharma Ireland Limited, a private limited company incorporated in Ireland (registered number 448848) whose registered address is Connaught House, 1 Burlington Road, Dublin 4, Ireland (“APIL”), and Recro Gainesville LLC, a Massachusetts limited liability company (successor to DV Technology LLC, “Purchaser,” and Purchaser shall include, after the Amendment Effective Date, any entity possessing the obligations of Purchaser set forth in the Agreement). Defined terms used but not defined herein shall have the meaning ascribed to such terms in the Agreement.
THIRD AMENDMENT TO ASSET TRANSFER AND LICENSE AGREEMENTAsset Transfer and License Agreement • August 21st, 2020 • Baudax Bio, Inc. • Services-misc health & allied services, nec • Delaware
This Third Amendment to Asset Transfer and License Agreement (this “Third Amendment”), dated August 17, 2020, entered into by and between Alkermes Pharma Ireland Limited, a private company limited by shares and incorporated in Ireland (“APIL”), Baudax Bio, Inc., a Pennsylvania corporation (“Baudax”) and Recro Gainesville LLC, a Massachusetts limited liability company (as successor to Recro Technology LLC f/k/a DV Technology LLC) (“Recro Gainesville” and together with Baudax and APIL, the “Parties”), amends that certain Asset Transfer and License Agreement, dated as of April 10, 2015 and amended on each of December 23, 2015 and December 20, 2018, by and among APIL and Recro Gainesville (and partially assigned to Baudax as set forth below) (as so amended and partially assigned, the “Agreement”).
ASSET TRANSFER AND LICENSE AGREEMENTAsset Transfer and License Agreement • May 4th, 2021 • Day One Biopharmaceuticals Holding Co LLC • Pharmaceutical preparations • Delaware
This Asset Transfer and License Agreement (“Agreement”) is made effective as of December 16, 2019 (the “Effective Date”) by and between DOT THERAPEUTICS-1, INC. (“Day One”), a Delaware corporation and an Affiliate of Day One Holdings, LLC, having a place of business at 2765 Sand Hill Road, Menlo Park, CA 94025, and MILLENNIUM PHARMACEUTICALS, INC. (“Takeda”), a Delaware corporation and an Affiliate of Takeda Pharmaceutical Company Limited, having a place of business at 40 Landsdowne Street, Cambridge, MA 02139.
ASSET TRANSFER AND LICENSE AGREEMENT - FGF-21Asset Transfer and License Agreement • October 11th, 2019 • 89bio, Inc. • Pharmaceutical preparations
THIS ASSET TRANSFER AND LICENSE AGREEMENT – FGF-21 (this “Agreement”), dated as of the 16th day of April, 2018 (the “Effective Date”), is by and between (a) 89Bio Ltd. (“Company”) on the one hand, and (b) Ratiopharm GmbH, Teva Branded Pharmaceutical Products R&D, Inc. and Teva Pharmaceutical Industries Ltd, (collectively “Teva”) on the other. Company, on the one hand, and Teva, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”
ASSET TRANSFER AND LICENSE AGREEMENT by and between Coherent, Inc. and Luna Innovations Incorporated Dated December 12, 2006Asset Transfer and License Agreement • April 6th, 2007 • Luna Innovations Inc • Services-commercial physical & biological research
This Asset Transfer and License Agreement (this “Agreement”) is entered into as of December 12, 2006 (the “Effective Date”) by and between Coherent, Inc., a Delaware corporation with a place of business at 5100 Patrick Henry Drive, Santa Clara, California 95054 (“Coherent”) and Luna Innovations Incorporated, a Delaware corporation with offices at 1703 S. Jefferson Street, SW, Suite 400, Roanoke, Virginia 24014 (“Luna”) (each, a “Party;” together, the “Parties”).
ASSET TRANSFER AND LICENSE AGREEMENTAsset Transfer and License Agreement • March 28th, 2022 • Prosper Funding LLC • Finance services • California
This ASSET TRANSFER AND LICENSE AGREEMENT (this “Agreement”), dated as of August 17, 2021 (the “Effective Date”), is entered into by and between Prosper Marketplace, Inc., a Delaware corporation (“PMI” or “Licensee”), and Prosper Funding LLC, a Delaware limited liability company and a wholly-owned subsidiary of PMI (“Prosper Funding” or “Licensor”). PMI and Prosper Funding are sometimes individually referred to herein as a “Party” and are sometimes collectively referred to herein as the “Parties.”
